A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma

NCT06739213 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Progressive High Grade Meningioma

Interventions

DRUG: SYHA1813
DRUG: Investigator's Choice Treatment

Sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd